Go to
current issue
-
Health care in Ukraine: If everybody leaves, who will stay? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-15 Talha Burki
No Abstract
-
Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Amy Shackleford, Liam G Heaney, Charlene Redmond, P Jane McDowell, John Busby
BackgroundClinical remission has emerged as an important treatment goal in severe asthma; however, studies have reported variable attainment due to differences in study populations, definitions, and methods. We aimed to perform a systematic review and meta-analysis of clinical remission attainment, definitions, and correlates among patients with severe asthma who have been treated with biologics. MethodsIn
-
Asthma remission: a call for a globally standardised definition Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Marek Lommatzsch, J Christian Virchow
No Abstract
-
Thoracentesis: an old story and some new sources Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-14 Emmanuel Drouin, Eric Wiel, Edouard Lansiaux, Jacalyn Duffin, Arnaud Chambellan
Section snippets Two late 18th century manuscriptsBoth of the manuscripts we feature here were written by students hearing the lectures of famous authors, but whose advice on thoracentesis is previously unknown. They are fascinating not only for expanding our understanding of these two important figures but because they provide precise descriptions of the site and technique of thoracic drainage just
-
Managing tuberculosis before the onset of symptoms Lancet Respir. Med. (IF 38.7) Pub Date : 2024-11-11 Dennis Falzon, Cecily Miller, Irwin Law, Katherine Floyd, Nimalan Arinaminpathy, Matteo Zignol, Tereza Kasaeva
No Abstract
-
Health promotion in the management of respiratory diseases: an Indian perspective Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-30 Arundhati Garud, Debabani Biswas, Saibal Moitra, Subhabrata Moitra
No Abstract
-
First-line treatment for advanced NSCLC in older patients and those with poor performance status Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Ziming Li, Shun Lu
No Abstract
-
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Hervé Léna, Laurent Greillier, Claire Cropet, Olivier Bylicki, Isabelle Monnet, Clarisse Audigier-Valette, Lionel Falchero, Alain Vergnenègre, Pierre Demontrond, Margaux Geier, Florian Guisier, Stéphane Hominal, Chrystèle Locher, Romain Corre, Christos Chouaid, Charles Ricordel
BackgroundCombined treatment with anti-PD-1 and anti-CTLA-4 antibodies has shown superiority over chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC), but data for older patients (aged ≥70 years) with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 or those with an ECOG performance status of 2 are scarce. We aimed to test the superiority of the PD-1 antibody
-
Spirometry in female individuals Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Martin R Miller, Brian L Graham, Sanja Stanojevic
No Abstract
-
Spirometry in female individuals – Authors' reply Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29 Philippe Haouzi, Johnathan McCully
No Abstract
-
Correction to Lancet Respir Med 2024; 12: 888–900 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29
No Abstract
-
Correction to Lancet Respir Med 2020; 8: 696–708 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-29
Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med 2020; 8: 696–708—In this Article, a subset of participants from the SPIROMICS cohort were included in the study who were later found to have not provided consent for genetics or to have withdrawn consent for genetics
-
The challenge of therapeutic options for patients with lymphangioleiomyomatosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-25 Maria Molina-Molina
No Abstract
-
Nintedanib for patients with lymphangioleiomyomatosis: a phase 2, open-label, single-arm study Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-25 Sergio Harari, Davide Elia, Antonella Caminati, Jens Geginat, Francesca Luisi, Giuseppe Pelosi, Claudia Specchia, Olga Torre, Roberta Trevisan, Chiara Vasco, Maurizio Zompatori, Roberto Cassandro
BackgroundLymphangioleiomyomatosis is an ultra-rare disease mainly affecting women of childbearing age. The MILES trial showed the efficacy of sirolimus, an mTOR inhibitor, in stabilising lung function in patients with lymphangioleiomyomatosis. Drug toxicity and development of resistance are potential limitations of therapy with sirolimus. Nintedanib is a multikinase inhibitor that inhibits PDGFR,
-
Youth vaping rates drop in US, but experts remain concerned Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-23 Bryant Furlow
No Abstract
-
UK COVID-19 booster vaccination programme Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-22 Priya Venkatesan
No Abstract
-
Correction to Lancet Respir Med 2024; 12: 799–809 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18
Yu J, Jiang L, Zhao L, et al. High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med 2024; 12: 799-809—In this Article, figure 2A had some labelling errors with regard to the number at risk and numbered censored. These corrections
-
Global, regional, and national burden of pulmonary arterial hypertension, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18
BackgroundPulmonary arterial hypertension (PAH) is a vascular disease characterised by restricted flow and high pressure through the pulmonary arteries, leading to progressive right heart failure and death. This study reports the global burden of PAH, leveraging all available data and using methodology of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) to understand the epidemiology
-
The global burden of pulmonary arterial hypertension: profound but improving? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-18 Joseph Newman, Joanna Pepke-Zaba
No Abstract
-
Mixed news on air pollution and child lung health Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-17 Udani Samarasekera
No Abstract
-
Breaking barriers: holistic assessment of ability to work in patients with sarcoidosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-16 Marjolein Drent, Anne-Marie Russell, Lesley Ann Saketkoo, Paolo Spagnolo, Marcel Veltkamp, Athol U Wells, representatives of the sarcoidosis community, Nicole Goh, Anne Holland, Johann Hochreiter, Selene Kock, Karolien Verheyen, Johan Verbraecken, André Cantin, Ashley Gillson, Nathan Hambly, Martin Kolb, Elisabeth Bendstrup, Anna Leistiko, Janne Møller, Riitta Kaarteenaho, Bruno Crestani, Dominique
No Abstract
-
Empirical antibiotic therapy for sepsis: save the anaerobic microbiota Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-11 Robert F J Kullberg, Bastiaan W Haak, Rishi Chanderraj, Hallie C Prescott, Robert P Dickson, W Joost Wiersinga
Antibiotics are fundamental in sepsis management; however, the optimal empirical treatment remains debated. Despite anaerobes rarely being the causative pathogen of sepsis, antibiotics targeting them are frequently used, which might lead to unintended consequences. Multiple studies have shown that depletion of commensal anaerobic gut microbes by anti-anaerobic antibiotics influences systemic immunity
-
Antimicrobial resistance: a global health emergency Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-11 The Lancet Respiratory Medicine
No Abstract
-
Survival of sepsis masked by medications that hid diverticulitis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-10 Tony Kirby
No Abstract
-
Airway inflammation enhances the effectiveness of elexacaftor–tezacaftor–ivacaftor therapy for cystic fibrosis and CFTRN1303K mutation Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-09 Martina Gentzsch, Charles R Esther Jr, Carla M P Ribeiro
No Abstract
-
Phillip Morris sell Vectura after academic freeze-out Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-08 Talha Burki
No Abstract
-
Towards shorter, safer, flexible, and more effective treatment regimens for drug-resistant tuberculosis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 Keertan Dheda, Christoph Lange
No Abstract
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 Ruth L Goodall, Andrew J Nunn, Sarah K Meredith, Adamu Bayissa, Anuj K Bhatnagar, Chen-Yuan Chiang, Francesca Conradie, Narendran Gopalan, Meera Gurumurthy, Bruce Kirenga, Nana Kiria, Daniel Meressa, Ronelle Moodliar, Nosipho Ngubane, Mohammed Rassool, Karen Sanders, Rajesh Solanki, S Bertel Squire, Mekonnen Teferi, Gabriela Torrea, Eve Worrall
BackgroundSTREAM stage 2 showed that two bedaquiline-containing regimens (a 9-month all-oral regimen and a 6-month regimen with 8 weeks of aminoglycoside) had superior efficacy to a 9-month injectable-containing regimen for rifampicin-resistant tuberculosis up to 76 weeks after randomisation. Our objective in this follow-up analysis was to assess the durability of efficacy and safety, including mortality
-
European Respiratory Society International Congress 2024 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-03 Priya Venkatesan
Section snippets Long-term oxygen therapy for severe hypoxaemiaTo prolong survival in patients with severe resting hypoxaemia, long-term oxygen therapy is an established treatment. The recommendation for oxygen use is for at least 15 h per day. Use for 24 h per day has been suggested to prolong survival according to a non-randomised comparison, however, the 24-h regimen can be burdensome, restrict
-
Confounding undermines inferences of preventive therapy effectiveness among subgroups of tuberculosis contacts Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 James Greenan-Barrett, Yohhei Hamada, Katherine L Fielding, Mahdad Noursadeghi, Rishi K Gupta
No Abstract
-
Anti-interleukin-4 receptor therapy for COPD with dupilumab? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-10-01 J Christian Virchow
No Abstract
-
Strengthening intensive care: addressing challenges and embracing opportunities Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-26 Elie Azoulay, Maurizio Cecconi, Jan J De Waele
-
Reflections 5 years on from the approval of ETI therapy Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-23 Peter G Middleton, Jennifer L Taylor-Cousar
-
Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-19 Prof Olivier Sitbon PhD, Andris Skride PhD, Jeremy Feldman MD, Sandeep Sahay MD, Oksana A Shlobin MD, Vallerie McLaughlin MD, Hossein-Ardeschir Ghofrani MD, David Langleben MD, Ed Parsley DO, Gwyn D'Souza MD, Tonya Marmon DrPH, Watiri Kamau-Kelley BS, Renee Jones BS, Ravi Grewal MSHS, Steve Wring PhD, Michelle Palacios PhD, Himanshu Naik PhD, Jill Denning MA, Howard M Lazarus MD, Prof Marc Humbert
The role of serotonin in pulmonary arterial hypertension has been extensively studied in recent decades, with preclinical data strongly indicating involvement in disease pathogenesis; however, clinical studies have yielded mixed results.
-
Serotonin pathway blockade in pulmonary arterial hypertension Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-19 Marcin Kurzyna
-
Stereotactic body radiotherapy plus neoadjuvant chemoimmunotherapy in operable non-small-cell lung cancer Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-18 Rafał Dziadziuszko, Bartłomiej Tomasik
-
Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-18 Ze-Rui Zhao, Shi-Liang Liu, Ting Zhou, Gang Chen, Hao Long, Xiao-Dong Su, Xu Zhang, Jian-Hua Fu, Peng Lin, Lan-Jun Zhang, Tie-Hua Rong, Jia-Di Wu, Zhi-Chao Li, Hui-Lin Su, Ji-Yang Chen, Yun-Peng Yang, Yong-Bin Lin, Mian Xi, Hong Yang
BackgroundNeoadjuvant immunotherapy with chemotherapy improves outcomes in patients with resectable non-small-cell lung cancer (NSCLC). Given its immunomodulating effect, we investigated whether stereotactic body radiotherapy (SBRT) enhances the effect of immunochemotherapy. MethodsThe SACTION01 study was a single-arm, open-label, phase 2 trial that recruited patients who were 18 years or older and
-
Extreme heat: holistic thinking in respiratory medicine Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-16 The Lancet Respiratory Medicine
-
Top ten research priorities for sepsis research: UK James Lind Alliance priority setting partnership Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-12 Joanne McPeake, Mark Oakes, Colin Graham, Nahid Ahmad, Nazir Lone, Bronwen Connolly, James Lind Alliance Sepsis PSP Steering Group, Kimberley Bradley, Walter Hall, Mike Mahoney, Clare Mahoney, Emily Perry, Yvonne Wiggan, Andrew Conway Morris, Paul Dark, Susan Moug, Simon Stockley, Jane Weaver
No Abstract
-
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 months Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-10 Charles S Haworth MBChB MD, Michal Shteinberg MD PhD, Prof Kevin Winthrop MD MPH, Prof Alan Barker MD, Prof Francesco Blasi MD PhD, Katerina Dimakou MD PhD, Prof Lucy C Morgan BMed PhD, Prof Anne E O'Donnell MD, Prof Felix C Ringshausen MD, Oriol Sibila MD PhD, Prof Rachel M Thomson PhD, Kevin J Carroll PhD, Federica Pontenani MD, Paola Castellani MD, Prof James D Chalmers MBChB PhD, PROMIS trial investigators
Chronic lung infection with Pseudomonas aeruginosa is associated with increased exacerbations and mortality in people with bronchiectasis. The PROMIS-I and PROMIS-II trials investigated the efficacy and safety of 12-months of inhaled colistimethate sodium delivered via the I-neb.
-
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-10 Yongfeng Yu, Qisen Guo, Yongchang Zhang, Jian Fang, Diansheng Zhong, Baogang Liu, Pinhua Pan, Dongqing Lv, Lin Wu, Yanqiu Zhao, Juan Li, Zhihua Liu, Chunling Liu, Haichuan Su, Yun Fan, Tongmei Zhang, Anwen Liu, Bo Jin, Ye Wang, Jianying Zhou, Shun Lu
BackgroundSavolitinib has been approved in China for advanced or metastatic non-small-cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations in previously treated patients and those unable to receive platinum-based chemotherapy. We report results from a treatment-naive cohort of a phase 3b study that was designed to evaluate the efficacy and safety of savolitinib in locally advanced
-
Savolitinib in NSCLC: progress in the MET exon 14 journey Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-10 Tetsuya Mitsudomi
-
PROMISing results for inhaled antibiotics in bronchiectasis Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-10 Marta María García Clemente, Guillermo Suárez Cuartín
-
The ongoing battle against breathlessness Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Kris Mooren, Huib A M Kerstjens
No Abstract
-
Respiratory syncytial virus infections in adults: a narrative review Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Joanne G Wildenbeest PhD, David M Lowe PhD, Prof Joseph F Standing PhD, Prof Christopher C Butler FMedSci
Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all ages, is increasingly recognised as an important pathogen in adults, especially among older people living with comorbidities. Distinguishing RSV from other acute viral infections on clinical grounds alone, with sufficient precision to be clinically useful, is not possible. The reference standard diagnosis is
-
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Prof Baohui Han MD, Trevor Feinstein MD, Prof Yuankai Shi MD, Prof Gongyan Chen MD, Prof Yu Yao PhD, Prof Chunhong Hu MD, Prof Jianhua Shi MD, Prof Jifeng Feng PhD, Huijuan Wu BMed, Ying Cheng MD, Prof Qi-sen Guo MMed, Zhijun Jie MD, Feng Ye MD, Prof Yiping Zhang MD, Prof Zhihua Liu MD, Prof Weidong Mao MS, Prof Liangming Zhang MD, Prof Junguo Lu BMed, Prof Jun Zhao MD, Prof Lyudmila Bazhenova MD,
There is an unmet need for second-line and third-line treatments that are effective and tolerable for advanced or metastatic non-small-cell lung cancer (NSCLC) with no driver mutations.
-
Plinabulin, a microtubule destabilising agent, in non-small-cell lung cancer: lessons from the DUBLIN-3 trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Rafael Rosell, María González-Cao, Miguel Angel Molina-Vila
-
Early-life respiratory syncytial virus disease and long-term respiratory health Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Prof Heather J Zar PhD, Ferdinand Cacho MD, Tahira Kootbodien PhD, Prof Asuncion Mejias MD, Prof Justin R Ortiz MD, Prof Renato T Stein MD, Prof Tina V Hartert MD
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI), hospital admission, and mortality in children worldwide. Early-life RSV LRTI has also been associated with subsequent long-term respiratory sequelae, including recurrent LRTI, recurrent wheezing, asthma, and lung function impairment, and these effects can persist into adulthood as chronic respiratory disease
-
Choice overload for RSV prevention—how to form your opinion Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Natasha Halasa, Louis Bont
-
Mirtazapine to alleviate severe breathlessness in patients with COPD or interstitial lung diseases (BETTER-B): an international, multicentre, double-blind, randomised, placebo-controlled, phase 3 mixed-method trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Prof Irene J Higginson FFPHM, Sarah T Brown MSc, Adejoke O Oluyase PhD, Peter May PhD, Prof Matthew Maddocks PhD, Massimo Costantini MD, Sabrina Bajwah PhD, Prof Charles Normand DPhil, Prof Claudia Bausewein PhD, Prof Steffen T Simon PhD, Prof Karen Ryan MD, Prof David C Currow PhD, Prof Miriam J Johnson MD, Simon P Hart PhD, Hannah Mather MSc, Prof Malgorzata Krajnik PhD, Silvia Tanzi PhD, Luca Ghirotto
Breathlessness frequently becomes severe among people with respiratory disease. Mirtazapine, a widely used antidepressant, has shown promise in the modulation of respiratory sensation and the response to it, as well as reducing feelings of panic, which often accompanies breathlessness. We aimed to determine the effectiveness of mirtazapine to alleviate severe persisting breathlessness.
-
Louis Bont – leading efforts to find an RSV vaccine Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-09 Tony Kirby
-
Continuing ECMO with no possible transition to recovery or transplant Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-05 Alexander Supady, William L Allen, Thaddeus M Pope
-
ECMO: more than just a bridge over troubled waters? Lancet Respir. Med. (IF 38.7) Pub Date : 2024-09-05 Ryan Ruiyang Ling, Kollengode Ramanathan, Kiran Shekar
-
Efficacy and safety of gefapixant in women with chronic cough and cough-induced stress urinary incontinence: a phase 3b, randomised, multicentre, double-blind, placebo-controlled trial Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-30 Prof Surinder S Birring MD, Prof Linda Cardozo MD, Prof Roger Dmochowski MD, Prof Peter Dicpinigaitis MD, Amna Afzal MD, Carmen La Rosa MD, Susan Lu PharmD, Allison Martin Nguyen MS, Ruji Yao PhD, Paul A Reyfman MD
Approximately two-thirds of women with chronic cough have cough-induced stress urinary incontinence (CSUI). We aimed to evaluate the efficacy and safety of gefapixant in reducing CSUI episodes in women with refractory or unexplained chronic cough.
-
Easing the stress of chronic cough Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-30 Marta Dąbrowska, Lorcan McGarvey
-
-
Further insights into MARS 2 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-28 Yumna Ahmed, Agha Muhammad Hammad Khan, Calogero Casa, Ahmed Nadeem Abbasi
-
Further insights into MARS 2 Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-28 Peter Zhan, Daniel J Boffa, Gavitt A Woodard
-
An international consensus on the use of asthma biologics in pregnancy Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-28 Jennifer Naftel, David J Jackson, Matthew Coleman, Grainne d'Ancona, Liam G Heaney, Paddy Dennison, Apostolos Bossios, Hitasha Rupani
Uncontrolled asthma is associated with an increased risk of adverse perinatal outcomes. Asthma biologics reduce exacerbation frequency, are steroid sparing, and improve quality of life in people with severe asthma. However, evidence for the use and safety of asthma biologics during pregnancy is scarce, largely because pregnant women were excluded from clinical trials. To help to support clinical teams
-
Navigating uncertainty: asthma biologics during pregnancy Lancet Respir. Med. (IF 38.7) Pub Date : 2024-08-28 Imran Howell, Aleksandra Howell, Ian Pavord
更新日期：2024-10-30
Copyright © 2014-2024 北京衮雪科技有限公司 All Rights Reserved
京ICP备11026495号-2
京公网安备 11010802027423号
京公网安备 11010802027423号